Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I

Paola Viliani, Renato Maserati, Mario B. Regazzi, Roberto Giacchino, Franco Lori

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In a prospective, randomized, controlled, three-arm study, the pharmacokinetics of hydroxyurea administered as an antiviral agent in patients infected with human immunodeficiency virus type 1 (HIV-1) were evaluated. The three arms of the study consisted of azidothymidine (AZT) 250 mg twice daily, hydroxyurea 500 mg twice daily, or a combination of the two. Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis. Sample collection was performed at steady-state conditions and serum concentration-time data for hydroxyurea were fitted using a one- compartment model. Mean (± standard deviation) peak concentration (C(max)) was 0.135 ± 0.06 mmol/L and mean trough level (C(min)) was 0.0085 ± 0.003 mmol/L. Mean concentration at steady state was 0.045 ± 0.006 mmol/L. Apparent clearance (Cl/F) was 0.18 ± 0.005 L/hr/kg, and half-life (t( 1/2 )) was 2.5 ± 0.5 hours. Hydroxyurea given orally to patients infected with HIV- 1 was well absorbed from the gastrointestinal tract, with a t(max) of 0.85 to 0.96 hours after ingestion. Serum levels of hydroxyurea ranged from 0.01 to 0.13 mmol/L. These values are similar to the concentrations (between 0.01 and 0.1 mmol/L) demonstrated to inhibit HIV-1 in vitro. Our data show that hydroxyurea given at a dosage of 500 mg twice daily is sufficient to yield serum concentrations potentially useful for in viva inhibition of HIV-1.

Original languageEnglish
Pages (from-to)117-121
Number of pages5
JournalJournal of Clinical Pharmacology
Volume36
Issue number2
Publication statusPublished - Feb 1996

Fingerprint

Hydroxyurea
Pharmacokinetics
HIV
HIV-1
Zidovudine
Serum
Phlebotomy
Antiviral Agents
Half-Life
Gastrointestinal Tract
Eating

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. / Viliani, Paola; Maserati, Renato; Regazzi, Mario B.; Giacchino, Roberto; Lori, Franco.

In: Journal of Clinical Pharmacology, Vol. 36, No. 2, 02.1996, p. 117-121.

Research output: Contribution to journalArticle

@article{e386345dda144b67bfaf942604adb4a0,
title = "Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I",
abstract = "In a prospective, randomized, controlled, three-arm study, the pharmacokinetics of hydroxyurea administered as an antiviral agent in patients infected with human immunodeficiency virus type 1 (HIV-1) were evaluated. The three arms of the study consisted of azidothymidine (AZT) 250 mg twice daily, hydroxyurea 500 mg twice daily, or a combination of the two. Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis. Sample collection was performed at steady-state conditions and serum concentration-time data for hydroxyurea were fitted using a one- compartment model. Mean (± standard deviation) peak concentration (C(max)) was 0.135 ± 0.06 mmol/L and mean trough level (C(min)) was 0.0085 ± 0.003 mmol/L. Mean concentration at steady state was 0.045 ± 0.006 mmol/L. Apparent clearance (Cl/F) was 0.18 ± 0.005 L/hr/kg, and half-life (t( 1/2 )) was 2.5 ± 0.5 hours. Hydroxyurea given orally to patients infected with HIV- 1 was well absorbed from the gastrointestinal tract, with a t(max) of 0.85 to 0.96 hours after ingestion. Serum levels of hydroxyurea ranged from 0.01 to 0.13 mmol/L. These values are similar to the concentrations (between 0.01 and 0.1 mmol/L) demonstrated to inhibit HIV-1 in vitro. Our data show that hydroxyurea given at a dosage of 500 mg twice daily is sufficient to yield serum concentrations potentially useful for in viva inhibition of HIV-1.",
author = "Paola Viliani and Renato Maserati and Regazzi, {Mario B.} and Roberto Giacchino and Franco Lori",
year = "1996",
month = "2",
language = "English",
volume = "36",
pages = "117--121",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I

AU - Viliani, Paola

AU - Maserati, Renato

AU - Regazzi, Mario B.

AU - Giacchino, Roberto

AU - Lori, Franco

PY - 1996/2

Y1 - 1996/2

N2 - In a prospective, randomized, controlled, three-arm study, the pharmacokinetics of hydroxyurea administered as an antiviral agent in patients infected with human immunodeficiency virus type 1 (HIV-1) were evaluated. The three arms of the study consisted of azidothymidine (AZT) 250 mg twice daily, hydroxyurea 500 mg twice daily, or a combination of the two. Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis. Sample collection was performed at steady-state conditions and serum concentration-time data for hydroxyurea were fitted using a one- compartment model. Mean (± standard deviation) peak concentration (C(max)) was 0.135 ± 0.06 mmol/L and mean trough level (C(min)) was 0.0085 ± 0.003 mmol/L. Mean concentration at steady state was 0.045 ± 0.006 mmol/L. Apparent clearance (Cl/F) was 0.18 ± 0.005 L/hr/kg, and half-life (t( 1/2 )) was 2.5 ± 0.5 hours. Hydroxyurea given orally to patients infected with HIV- 1 was well absorbed from the gastrointestinal tract, with a t(max) of 0.85 to 0.96 hours after ingestion. Serum levels of hydroxyurea ranged from 0.01 to 0.13 mmol/L. These values are similar to the concentrations (between 0.01 and 0.1 mmol/L) demonstrated to inhibit HIV-1 in vitro. Our data show that hydroxyurea given at a dosage of 500 mg twice daily is sufficient to yield serum concentrations potentially useful for in viva inhibition of HIV-1.

AB - In a prospective, randomized, controlled, three-arm study, the pharmacokinetics of hydroxyurea administered as an antiviral agent in patients infected with human immunodeficiency virus type 1 (HIV-1) were evaluated. The three arms of the study consisted of azidothymidine (AZT) 250 mg twice daily, hydroxyurea 500 mg twice daily, or a combination of the two. Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis. Sample collection was performed at steady-state conditions and serum concentration-time data for hydroxyurea were fitted using a one- compartment model. Mean (± standard deviation) peak concentration (C(max)) was 0.135 ± 0.06 mmol/L and mean trough level (C(min)) was 0.0085 ± 0.003 mmol/L. Mean concentration at steady state was 0.045 ± 0.006 mmol/L. Apparent clearance (Cl/F) was 0.18 ± 0.005 L/hr/kg, and half-life (t( 1/2 )) was 2.5 ± 0.5 hours. Hydroxyurea given orally to patients infected with HIV- 1 was well absorbed from the gastrointestinal tract, with a t(max) of 0.85 to 0.96 hours after ingestion. Serum levels of hydroxyurea ranged from 0.01 to 0.13 mmol/L. These values are similar to the concentrations (between 0.01 and 0.1 mmol/L) demonstrated to inhibit HIV-1 in vitro. Our data show that hydroxyurea given at a dosage of 500 mg twice daily is sufficient to yield serum concentrations potentially useful for in viva inhibition of HIV-1.

UR - http://www.scopus.com/inward/record.url?scp=0029923839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029923839&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 117

EP - 121

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 2

ER -